Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Squamous Cell Carcinoma of the Head and Neck (US/EU)
The angiogenesis inhibitor Erbitux, in combination with platinum-based therapy and 5-fluorouracil (5-FU), was the standard treatment option for all squamous cell carcinoma of the head and neck (SCCHN) patients in the first-line recurrent or metastatic setting. The approval of immune checkpoint inhibitors—Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb)—in the first-line setting over the last decade has changed the treatment paradigm for recurrent or metastatic SCCHN patients as monotherapy and/or in combination with platinum + 5-FU. However, there is a strong need for effective therapies in this patient setting. This report provides a detailed analysis of the factors that influence medical oncologists’ prescribing decisions and reviews the unmet needs that novel therapies should confront.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in medical oncologists’ prescribing decisions for non-nasopharyngeal SCCHN?
- How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunity that drug developers could leverage in the treatment of non-nasopharyngeal SCCHN?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical target product profile for non-nasopharyngeal SCCHN?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 33 European medical oncologists fielded in December 2021
Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly
Key drugs: Erbitux, Keytruda, Opdivo
Table of contents
- Squamous Cell Carcinoma of the Head and Neck - Unmet Need - Unmet Need - Squamous Cell Carcinoma of the Head and Neck (US/EU)
- Unmet Need - Recurrent or Metastatic Non-Nasopharyngeal SCCHN - TPP Simulator - March 2022
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN
- Importance of efficacy attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Importance of safety and tolerability attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Importance of safety and tolerability attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Importance of convenience of administration attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Overall Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Mean overall performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN: United States and Europe
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select efficacy attributes: United States
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select efficacy attributes: Europe
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Safety and Tolerability Attributes: United States
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select safety and tolerability attributes: Europe
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Convenience of Administration Attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in recurrent or metastatic non-nasopharyngeal SCCHN
- Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Key findings: unmet need in recurrent or metastatic non-nasopharyngeal SCCHN and related indications
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Recurrent or Metastatic Non-Nasopharyngeal SCCHN and Related Indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in recurrent or metastatic non-nasopharyngeal SCCHN and related indications: Europe
- Opportunity analysis
- Target product profiles
- Appendix
Related Market Assessment Reports
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
